Evaluation of Beta-lactam antibacterials and penicillins consumption

Abstract

Background: The beta-lactam family of antibiotics includes the majority of the most heavily used antibacterials in clinical medicine. They are important, both historically and currently, because of their effectiveness and generally low toxicity. All around the world in hospitals consumption recorded in medium 30-50% of all antibiotics and that situation determined higher attention for dynamic use study of beta-lactam antibacterials and penicillins in hospitals. Material and methods: For this study we used data of a six-year (2009-2014) period, in the Emergency Medicine Institute and their subdivisions with the highest consumption of antibiotics which shows the dynamics of the use of beta-lactam antibacterials and penicillins in grams and value indexes. Results: In the evaluated period consumption of beta-lactam antibacterials and penicillins in EMI recorded a decline from 85.5 to 20.8 DDD/1000 or by 75.67%, in ICD departments from 367.92 to 133.91 DDD/1000 or by 63.60%, and respectively from 74.48 to 39.31 DDD/1000 in SSOTD or by 19.84%. Medium annual consumption in EMI recorded 65.42 DDD/1000 and respectively in ICD 178.29 and 73.68 DDD/1000 in SSOTD departments, while in international hospitals medium consumption constitutes 354.3 and in ICU 575 DDD/1000. In 2014 ICD departments recorded 6549.28 lei per DDD/1000 that was by 6.12 times more than the cost of 1069.62 lei registered in SSOTD departments and by 11.49 times than 569.84 lei recorded per DDD/1000 in all EMI. Conclusions: In the evaluated period, EMI recorded the consumption of beta-lactam antibacterials and penicillins by 5.42 times less comparatively to 354.3 DDD/1000 registered in some international hospitals, which could be considered an important point for reviewing antimicrobial treatment of the hospitalized patients, as well as annual planning optimization and rational use of this group and all antibiotics necessities.